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Abstract 
A double blind, placebo-controlled and randomized study was conducted at Stockholm 
Marathon 2011. The aim was to investigate if egg yolk powder B 221 with high levels of 
Antisecretory factor could decrease the prevalence of diarrhea among runners that had ex-
perienced diarrhea at >50% of their marathon races. The study did not reach the planned 
number of 200 study subjects and also encountered problems with dropouts. The number 
of study subjects was 55 on the day of the marathon. There was no significant difference 
between placebo and active treatment (p=0.23). The prevalence of diarrhea was 59% (B 
221) and 43% (placebo), respectively. The study could not show that a diet supplemented
with B 221 had a decreasing effect on the prevalence of diarrhea in the studied population
during the day of the marathon race.
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1 Introduction 
1.1 Gastrointestinal disturbances among runners 
Runners are not the only athletes suffering from gastrointestinal disturbances, but 
runners as a group has been reported peaking in prevalence (Peters, 1999). Table 1 
summarizes the findings from four different studies on gastrointestinal disturb-
ances among marathon runners. As seen in Table 1 32 to 42 percent of the re-
spondents experienced a strong urge to defecate when running marathon races. 
Moreover about 20 percent of marathon runners suffer from diarrhea during, under 
or after a finished race. Other common problems are heartburn, nausea, vomiting, 
cramps in the gastrointestinal tract, stomach-ache and side ache (Keeffe et al., 
1984; Riddoch & Trinick, 1988; Sullivan & Wong 1992). 
 
Many factors have been suggested for causing the disturbances; mental stress, ex-
haustion, low blood sugar and increased activity in the sympathetic nervous sys-
tem, hence affecting the gastrointestinal system are some examples. As the intensi-
ty of the physical activity increases more blood is redirected from the gastrointes-
tinal system to the muscles, which could lead to a decreased function (Baska et al., 
1990; Sawka & Young, 2005). Another potential factor for diarrhea is intracellular 
disturbances in electrolytes as a result of endurance exercise, hence leading to de-
creased smooth muscular and mucosal function (Keeffe et al., 1984). 
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Table 1. Percentage of long distance runners reporting different gastrointestinal symptoms in 
four different studies.  
Symptom/Study Keeffe et al., 
1984. 
Riddoch & 
Trinick, 1988. 
Rehrer & 
Janssen, 
1989. 
Sullivan & 
Wong, 1992. 
Loss of appetite (%) - 28 - - 
Heartburn (%) 10 13 - 24 
Nausea  (%) 12 20 11 - 
Vomiting (%) 2 4 - - 
Abdominal Cramps (%) 19 31 - 35 
Urge to defecate (%) 37 42 - - 
Diarrhea (%) 19 27 0 - 
Stomach ache (%) - - 25 - 
Side ache (%) - - 23 - 
Intestinal cramps (%) - - 18 - 
 
Yet another factor that might influence the prevalence of diarrhea among runners 
are sport drinks and sport gels with a carbohydrate level from 7-10% and above. 
When these products are consumed the high carbohydrate level in the gut will, by 
osmosis, draw fluid into the colonic tract, resulting in diarrhea or an urge to defe-
cate (Rehrer & Janssen, 1989).  
1.2  Antisecretory factor, Special processed cereals, and  
B 221 
In 1987 Ivar Lönnroth and Stefan Lange concluded that specific carbohydrates and 
amino acids have a positive effect on the endogenous production of the protein 
Antisecretory factor, AF (Lange & Lönnroth, 1987). AF is a highly preserved pro-
tein and can be found in all mammalian species in the most tissues of the body 
(Lange et al., 1999).  
 
Animal studies have shown an increase of AF production when subjects are ex-
posed to enterotoxins (Lange & Lönnroth, 2001) and in another study AF has been 
proven to decrease the diarrheal and inflammatory effect of bacterial enterotoxins 
like cholera toxin which is produced by the bacteria Vibrio cholerae (Johansson et 
al., 1997).  
 
AF has also been seen to inhibit the cytotoxic- and inflammatory action of toxin 
A. Toxin A is an endotoxin from the gram-positive Clostridium difficile species. 
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Further, the authors suggest that AF might be part of the defense against dehydra-
tion and inflammation caused by enterotoxins. It has been suggested that too low 
levels of AF might be the reason for piglet diarrhea (Lange et al., l987). 
 
In a study on patients suffering from long-standing symptoms of inflammatory 
bowel disease, IBD, study subjects were given special processed cereals (SPC) or 
untreated cereals. SPC are cereals that have been hydrothermally treated in a pro-
cess that has similarities with malting. The process alters the amounts of sugars 
and amino acids in the cereals. Table 2 displays the changes in carbohydrate and 
amino acid composition before and after hydrothermal treatment of the cereals. 
Study subjects given SPC showed higher levels of AF in their blood than study 
subjects that had received untreated cereals. Further, study subjects given SPC 
reported improved ratings of clinical symptom. No significant change in the clini-
cal symptom rating could be seen in the group of study subjects that had been giv-
en untreated cereals (Björck et al., 2000).  
Table 2. The change in amounts of 4 types of carbohydrates and 5 types of amino acids per gram 
of dry matter before and after the specific hydrothermal treatment (Björck et al., 2000). 
 
 
Before hydrothermal treat-
ment (mg/g DM) 
After hydrothermal treatment 
(mg/g DM) 
Glucose 0.3–0.4  0.6–5.3 
Fructose 0.3–0.4  0.6–3.1 
Sucrose 8.4–14.4  36.8–65.7 
Maltose 0 4.0–9.0 
Histidine 0 0.06–0.25 
Glutamic acid 0.12–0.20  0.42–0.44 
Lysine 0.03–0.06  0.15–0.29 
Tryptophan 0.09–0.22  0.28–0.45 
Isoleucine 0 0.05–0.30 
 
AF is a lectin carbohydrate-binding protein that has been shown to have hormone‐
like properties, with the capacity to regulate water and electrolyte transport in the 
small intestine and thus been investigated and used in threating different condi-
tions of diarrhea (Lange et al., 1994).   
 
AF levels may be negatively affected by stress. In an experiment, rats that either 
were subjected to experimentally induced stress or given an injection of the stress 
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hormone adrenocorticotropine showed a decrease in AF levels in blood and in the 
pituitary gland (Ulgheri et al., 2010).  
 
As illustrated in Fig 1, hens that have been fed SPC feedstuff will spawn eggs that 
contain high amounts of AF in the yolk. The yolk is spray dried and packaged in 
sachets. The product is named B 221 when used in scientific research (Zaman et 
al., 2007). B 221 is also marketed under the consumer brand name Salovum®. The 
product is on the Swedish national list of products for special nutrition / medical 
purposes (LVFS 2010:27) which is issued by Medical Products Agency Sweden 
(Läkemedelsverket).  
 
 
 
 
 
 
 
 
Figure 1. Illustration of how laying hens fed SPC-feed stuff lay eggs rich in AF. Spray drying of these 
egg yolks results in the egg yolk powder B 221 or Salovum®. 
1.3 B 221 studies 
 In a study on acute diarrheal symptoms in children aged 6 to 24 months, subjects 
who were given anti secretory proteins in concentrated form B 221 showed a sig-
nificantly faster recovery rate than subjects who were given placebo (Zaman et al., 
2007).  
 
A smaller study on endocrine diarrhea, four patients with mid-gut carcinoid syn-
drome and two with metastasizing medullary thyroid carcinoma, MTC, reported 
significantly  (p<0.01) fewer daily bowel movements when treated with B 221. 
Daily bowel movements decreased from an average of 5.6 to 4.2. Further, the 
study reported an increase in formed stools. Before treatment with B 221 started, 
study subjects recorded the consistency of their stools during one week with a re-
ported number of 14% formed stools. During the last week of a total of 4 weeks 
treatment with B 221, the reported number of formed stools was 41% (Laurenius 
et al., 2003).  
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1.4 AF mode of action  
AF interacts with the protein flotillin-1. Flotillin-1 is present in a structure in cell 
membrane named “lipid rafts”. Lipid rafts are thicker areas of the cell membrane 
enriched with sphingolipids and cholesterol. Lipid rafts house large protein com-
plexes due to the extra space available. The proteins found in lipid rafts often play 
a role in intracellular communication pathways; making lipid rafts a common tar-
get for viruses and other virulence factors. Cholera toxin (CT) from Vibrio chol-
erae and Escherichia coli heat labile toxin (LT) both bind to a ganglioside named 
GM-1, commonly attached to flotillin-1. When bound, the two toxins activate dif-
ferent signal transduction pathways both resulting in diarrhea. The binding of AF 
to flotillin-1 has been proposed to alter the characteristics of the lipid rafts. Bind-
ing leads to a change in the positions of signal proteins and their receptors, there-
fore decreasing the effect of toxins that cannot find a binding point (Ulgheri et al., 
2010).  
1.5 Aim 
The aim of this study was to investigate if a diet complemented with egg yolk 
powder high in Antisecretory factor, AF, could have a reducing effect on the prev-
alence of diarrhea among runners participating in the Stockholm Marathon which 
was held on the 28th of May 2011. 
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2 Materials and Methods 
 
2.1 Ethical approvement 
The Ethical Review board of Uppsala University approved this study.   
2.2 Study Population 
A total of 5732 runners (74% male, 26% female) were contacted via the Stock-
holm Marathon register with the use of an e-mail marketing service. Runners who 
were interested and who judged themselves to meet the inclusion/exclusion criteria 
were asked to fill in a questionnaire regarding body measurements and their histo-
ry of gastrointestinal disturbances on the study web-page. 
 
The number of runners that filled in the screening questionnaire was 169 (61% 
male, 39% female). The answers were reviewed by the study doctor and checked 
against the inclusion/exclusion criteria in Table 3.  The number of runners meeting 
all criteria and that was intended to be the study population was 103. 
Table 3. The inclusion and exclusion criteria of the study. 
Inclusion criteria: 
• Will participate in the 2011 Stockholm Mara-
thon 
• 18 years old or older 
• Healthy 
• History of gastrointestinal disturbances in con-
nection to running in at least half of total par-
ticipated races  
• Participated in at least one marathon 
Exclusion criteria 
• Chronic gastrointestinal dis-
ease  
• Allergic to egg 
• Prone to constipation 
• On a diet with SPC - Flakes 
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 2.3 Design 
The study design was of the type randomized, placebo controlled and double 
blind. Study subjects were randomly assigned to two different groups with 50% of 
the study subjects in each group. The total time of treatment was three days.  
 
Table 4 is showing the demography data of the 55 study subjects that fulfilled the 
study. The active group consisted of 17 male and 11 female study subjects and the 
control group consisted of 21 male and 6 female study subjects.  The overall com-
position of study subjects was 78% male and 32% female. 
Table 4. Demography of the 55 study subjects. Range within brackets. 
Gender Treatment n Age 
(years) 
Height  
(cm) 
Bodyweight 
(kg) 
Male B 221 17 41.2  
(26 / 53) 
181.2 (159 / 193) 76.6  (57 / 93) 
 Placebo 21 40.9  
(29 / 65) 
182.0 (172 / 195) 79.2 (71 / 88) 
Female B 221 11 39.0  
(24 /58) 
169.2 (163 / 175) 60.0 (54 / 71) 
 Placebo 6 40.5  
(27 / 50) 
168.7 (160 / 175) 59.9 (48 / 72) 
 
Calculation of sample size was done using a two-sided Chi-square test at a 0.05 
significance level and 80 % power. Results show that at least 82 subjects per 
group are needed to detect an absolute difference between treatments of 20 per-
centage points or more. Power calculation was done using Nquery 6.02.  
2.4 Defining diarrhea 
 
The primary efficacy variable was the prevalence of diarrhea on the day of the 
race.  
 
The Bristol Scale Stool Form, see Figure 2, is an instrument to classify the form 
and consistency of stools (Lewis & Heathon, 1997). To be able to classify if study 
subjects experienced diarrhea or not, the commonly used Bristol Scale Stool Form 
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was sent to the study subjects. Study Doctor Stefan Branth scrutinized Swedish 
translation.  
 
Diarrhea was defined as type 6 and 7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  The Bristol Stool Form Chart with descriptions to the left 
and English descriptions on the right. Water painting by Elisabeth Köhlerstrand. 
 
Study subjects classification of stool forms were sent in via an online form. Stool 
form charts were to be filled in by study subjects during five days; the three days 
with diet supplementation and two days thereafter. Data was collected for a total 
of five days to be able to track adverse effects of the treatments.  
 
 
Type 1: Separate hard lumps, like nuts. 
 
 
Type 2: Sausage-shaped, but lumpy. 
 
 
Type 3: Like a sausage but with cracks on its surface 
 
 
Type 4: Like a sausage or snake, smooth and soft 
 
 
Type 5: Soft blobs with clear-cut edges (passed easily). 
 
 
Type 6: Fluffy pieces with ragged edges, a mushy stool 
 
 
Type 7: Watery, no solid pieces. Entirely liquid. 
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2.5 Study treatments  
Study subjects included in the study were instructed to eat a supplementary diet 
according to the scheme in Table 5. 
Table 5. Study subjects were instructed to eat the study product on a total of 8 occasions. The 
weight of one sachet of egg yolk powder was 4 gram.  
Day 1 
 
Day 2 Day 3  
Stockholm Marathon 
Breakfast 
Lunch 
Dinner 
4g 
4g 
4g 
Breakfast 
Lunch 
Dinner 
8g 
8g 
8g 
Breakfast 
After finish 
 
24g 
12g 
 
 
Each study subject was randomly assigned to either B 221 or placebo (standard 
spray-dried egg yolk powder) treatment. No restrictions were given except that 
study subjects were not allowed to eat SPC products. 
 
Code lists were not available for persons directly involved in the study. B 221 and 
placebo were manufactured by Källbergs AB. B 221 and placebo were packed in 
identically looking sachets, each containing 4 g of product.  
 
Taste and appearance of B 221 and placebo was equal. Different time stamps on 
the sachets could separate B 221 and placebo. Sachets containing placebo had 
been tested not to contain AF.  
 
Lantmännen AS-Faktor AB conducted the packaging and distribution. 
The study subjects received the study product by mail. No collection of unused 
product was carried out. 
2.6 Statistics 
 
Mean values of the prevalence of diarrhea were calculated. The difference be-
tween the two treatments was evaluated using Students t-test.  
The level of significance tested was 95%.   
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3 Results and Discussion 
 
Table 6 shows that the active group had 29 study subjects filing their data on the 
first day of the study and that the group had one study subject dropping out during 
the study. The placebo group decreased from 28 to 25 reporting study subjects in 
the same time interval. In the placebo group 1 person dropped out of study on the 
day of the race and 2 more dropped out on the 4th day. 
Table 6.  The number of study subjects that delivered their diaries on the different days of the 
study. 
Treatment Day 1 Day 2 Day 3 
Stockholm Marathon 
Day 4 Day 5 
Active 29 29 28 28 28 
Placebo 28 28 27 25 25 
Active + Placebo 57 57 55 53 53 
 
Table 7 presents the prevalence of diarrhea in the two groups on the day of the 
race. On the day of the race 55 study subjects filed their answers. The active group 
consisted of 28 study subjects and 17 of them, 10 men and 7 women, experienced 
diarrhea. The placebo group consisted of 27 study subjects and 12 of them, 9 men 
and 3 women, experienced diarrhea. In percentage, 61% in the active group and 
43% in the placebo group experienced diarrhea on the day of the race. The differ-
ence between the two treatments was not significant (p=0,23). The low number of 
study subjects included in the study together with the large amount of drop-outs 
lead to an uneven distribution of male and female study subjects between the 
groups.  
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Table 7. The number of male and female study subjects that experienced diarrhea on the day of 
the marathon race. 
Treatment Male Female Total 
B 221 10 (59% of the men) 7 (58% of the women) 17 (61% of the 
whole group) 
Placebo 9 (41% of the men) 3 (50% of the women) 12 (43% of the 
whole group) 
 
 
Study subjects that did not send in complete data for all five days were asked to 
clarify why they did so in a mail-based post study drop out survey. A total of 28 
intended study subjects replied on the survey.  Dropout reasons and the number of 
study subjects agreeing with respective reasons are presented in Table 8. Several 
dropouts were connected to sickness and injuries. Other dropouts were connected 
to the fact that the B221 is an unknown product and the study subjects did not 
want to jeopardize their performance. Too extensive work with data registration 
has also been reported as a dropout factor. Only 3 study subjects reported that their 
reason of dropout was that they had problems with ingestion of the egg-powder.  
 
Table 8. Seven different reasons for drop-out reported by the 28 intended study subjects that re-
sponded to a post study survey. 
Did not participate in the marathon 8 
Injured 4 
Sick 5 
Did not get the study product in time 5 
Was not able to drink/eat the egg powder 3 
Did not want to risk the result of the marathon by 
testing, an in the context, untested product. 
6 
 
Too many questions to answer 6 
Data registration problems 4 
  
Study subjects were asked to report health issues during the five days of the study. 
The number of reported adverse events was 16 for the group receiving B 221 and 
24 for the group that received placebo.   
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Further, which can be seen in Table 9, there was as difference in the number of 
reported adverse events in the two groups: the active group reported 16 adverse 
events during all 5 days of the study and the placebo group reported 24 adverse 
events for the same time. 
Table 9. Summary of reported adverse events in the two groups. 
Day 1-5 B 221 Placebo 
Headache 11 6 
Throat ache 1 3 
Nausea 2 1 
Cold 1 9 
Dehydration - 1 
Cramp - 2 
Sore muscles 1 2 
Total 16 24 
 
 
Table 10 summarizes reported adverse events on 1st day of the study. A total of 12 
adverse events were reported in 4 categories: headache, throat ache, nausea and 
cold. Active group reported 4 adverse events and the group given placebo reported 
8. 
Table 10.  Number of study subjects that received B 221 or placebo and of whom reported health 
problems during the first day of the study. 
Day 1 B 221 Placebo 
Headache 2 4 
Throat ache 1 1 
Nausea 1 - 
Cold - 3 
Dehydration - - 
Cramp - - 
Sore muscles - - 
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Table 11 summarizes reported adverse events on the 2nd day of the study. A total 
of 6 adverse events were reported in 2 categories: headache and cold. 
Table 11. Number of study subjects that received B 221 or placebo and of whom reported health 
problems during the second day of the study. 
Day 2 Active Placebo 
Headache 2 1 
Throat ache - - 
Nausea - - 
Cold - 3 
Dehydration - - 
Cramp - - 
Sore muscles - - 
 
 
Table 12 summarizes reported adverse events on the 3rd day of the study. A total 
of 5 adverse events were reported in 4 categories: headache, nausea, dehydration 
and cramp. 
Table 12. Number of study subjects that received B 221 or placebo and of whom reported health 
problems during the third day of the study. 
Day 3 Active Placebo 
Headache 2 - 
Throat ache - - 
Nausea 1 - 
Cold - - 
Dehydration - 1 
Cramp - 1 
Sore muscles - - 
 
  
 15 
 
Table 13 summarizes reported adverse events on the 4th day of the study. A total of 
9 adverse events were reported in 5 categories: headache, throat ache, nausea, 
cramp and sore muscles. 
Table 13. Number of study subjects that received B 221 or placebo and of whom reported health 
problems during the fourth day of the study. 
Day 4 Active Placebo 
Headache 4 - 
Throat ache - 1 
Nausea - 1 
Cold - - 
Dehydration - - 
Cramp - 1 
Sore muscles 1 1 
 
 
 
Table 14 summarizes reported adverse events on the 5th day of the study. A total of 
8 adverse events were reported in 5 categories; headache, throat ache, nausea, 
cramp and sore muscles. 
Table 14. Number of study subjects that received B 221 or placebo and of whom reported health 
problems during the fifth day of the study. 
Day 5 Active Placebo 
Headache 1 1 
Throat ache - 1 
Nausea - - 
Cold 1 3 
Dehydration - - 
Cramp - - 
Sore muscles - 1 
 
 
The main issue with the study was that it did not reach the planned number of 
study subjects entering and completing the study. The plan was to enroll 200 study 
subjects in the study, 100 subjects in each group. Out of the 169 runners that sent 
in their screening data 103 did actually meet the study criteria.  
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The study was performed at one single event only to create as similar conditions as 
possible in factors that possibly could have had an impact on the study subjects; 
weather, running course and stress (Ulgheri et al., 2010). However, diet is a factor 
that was not controlled and this could have affected the outcome of the study 
(Rehrer & Janssen, 1989). 
 
The study gives an indication that B 221, in the dose that was administrated in the 
study, does not diminish the prevalence of diarrhea among runners with a history 
of diarrhea in connection with long distance running.  More information, meeting 
with the study doctor could possibly have diminished the amount of dropouts. A 
pilot study prior to the marathon could have given important experiences and data 
for the study design. 
4 Conclusion 
This study could not show support for the hypothesis that a treatment with egg 
yolk powder high in Antisecretory factor, AF, had a reducing effect on the preva-
lence of diarrhea among marathon runners. The prevalence of diarrhea was lower 
in the placebo group. However, the low number of study subjects does not allow 
for any conclusions. 
 
No data on dose in healthy individuals was available when the study was designed. 
It is possible that the dose was too low. For future studies a key element would be 
to include a proper dose finding titration. Further, no severe side effects of the 
treatment were reported in either group, a finding that can be used in future design 
of studies with B221 and athletes.  
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Appendix 1 – Popular Scientific Summary 
Gastrointestinal disturbances during and/or after running, commonly known as 
“runner’s trots”, are common among marathon runners. In previous studies about 
one third of the marathon runners reported that they had suffered from diarrhea in 
connection to marathon runs and about one third reported that they had a strong 
urge to defecate.  
 
The cause of these disturbances has not yet been determined. The redirection of 
blood from the gut to the skeletal muscles is one factor that is believed to affect 
the function of the gastrointestinal system. Other commonly mentioned factors are 
stress, low blood sugar and ingestion of sweeter sport drinks.  
 
 In 1984 the scientists Stefan Lange and Ivar Lönnroth at the University of 
Gothenburg discovered a protein with anti-inflammatory and anti-secretory prop-
erties. The protein was later named Antisecretory Factor (AF). B221 is a spray-
dried egg yolk powder with a high content of AF. This powder has in earlier stud-
ies successfully stopped acute and persisting diarrheas among young children and 
diarrhea as a result of chemo- and radiation therapy.   
 
A number of 103 runners intending to participate in the 2011 Stockholm Marathon 
and who had an extensive history of diarrhea in connection to marathon running 
were selected for the study. The runners complemented their normal diet with 
B221 or common egg yolk powder (placebo) two days prior to and on the day of 
the race. The runners did not know if they had been given B221 or placebo. Dur-
ing these days and two days thereafter (a total of five days) the runners reported 
their stool consistency using a visual guidance complemented with explanations.   
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Unfortunately the study suffered from many dropouts. Many of the dropouts were 
connected to sickness and injuries. Other runners did not want to jeopardize the 
outcome of the race with an unknown product. Some reported that the egg powder 
had arrived to late or that there was too many questions to answer. 
 
This study could not show support for the hypothesis that a treatment with egg 
yolk powder high in Antisecretory factor, AF, had a reducing effect on the preva-
lence of diarrhea among marathon runners. The number of runners that reported 
their stool consistency on the day of the race was 55. The group receiving the 
B221 had a slightly higher percentage of diarrheas on the day of the race than the 
placebo group. However, the difference between the two groups was not statisti-
cally significant. That is, there is a possibility that the outcome was due to chance.  
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